Zoetis(ZTS) ZACKS·2025-05-06 13:15Company Performance - Zoetis reported quarterly earnings of $1.48 per share, exceeding the Zacks Consensus Estimate of $1.40 per share, and showing an increase from $1.38 per share a year ago, representing an earnings surprise of 5.71% [1] - The company posted revenues of $2.22 billion for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.35% and showing growth from $2.19 billion year-over-year [2] - Over the last four quarters, Zoetis has consistently surpassed consensus EPS and revenue estimates [2] Stock Outlook - The immediate price movement of Zoetis shares will largely depend on management's commentary during the earnings call, with shares down about 3% year-to-date compared to the S&P 500's decline of 3.9% [3] - The current consensus EPS estimate for the upcoming quarter is $1.59 on revenues of $2.38 billion, and for the current fiscal year, it is $6.07 on revenues of $9.31 billion [7] Industry Context - The Medical - Drugs industry, to which Zoetis belongs, is currently ranked in the top 22% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact Zoetis's stock performance [5]